The University of Nevada, Reno School of Medicine

Charting the Course to Higher Targets With JAK Inhibition in Atopic Dermatitis

Identify strategies to counsel patients about higher treatment targets in moderate-to-severe atopic dermatitis (AD) management 

Discuss safety and efficacy data for approved and emerging Janus kinase (JAK) inhibitors in moderate-to-severe AD 

Apply safety data for JAK inhibitors to therapeutic selection for patients with moderate-to-severe AD 